AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Lupron (leuprolide) [legacy through FY21] by Year
Lupron (leuprolide) [legacy through FY21] — U.S. reported growth YoY (%) (%)
AbbVie Lupron (leuprolide) [legacy through FY21]: 0.5% in FY2021, up 17.1 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2021 figure comes from
“|| Lupron | 604 | 179 | 783 | 0.5 | 18.0 | 4.0 | 0.5 | 15.0 | 3.4”
Source: Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lupron (leuprolide) [legacy through FY21] — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 0.5% | +17.1 pts | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | -16.6% | -15.8 pts | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
| FY2019 | Dec 31, 2019 | -0.8% | -9.4 pts | Form 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗ |
| FY2018 | Dec 31, 2018 | 8.6% | +7.8 pts | Form 8-K (abbv-20181231xexhibit991.htm, filed 2019-01-25) ↗ |
| FY2017 | Dec 31, 2017 | 0.8% | – | Form 8-K (abbv-20171231xexhibit991.htm, filed 2018-01-26) ↗ |
Cite this data
StockData. (2026). AbbVie Lupron (leuprolide) [legacy through FY21] (%), annual FY2017–FY2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lupron-us-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.